IL22 and metabolic disease: Studies have shown that metabolic disorders and gut dysbiosis reduce the microbiota’s ability to metabolize tryptophan, leading to decreased production of GLP-1 and IL-22, increased intestinal permeability, and LPS translocation, which contribute to inflammation, insulin resistance, obesity, and liver steatosis.